The document discusses Bayer Corporation's recall of products containing the ingredient phenylpropanolamine (PPA) due to health concerns raised by the FDA. It provides background on Bayer, describes the controversy around PPA and studies linking it to risks of hemorrhagic stroke. It outlines the FDA's process for evaluating drug risks and requesting voluntary recalls. When the FDA recommended discontinuing PPA use, some media incorrectly reported this as an outright ban, which failed to anticipate how this would impact perception of Bayer's Alka-Seltzer brand.
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014Sathish Vemula
To recap the previous month's pharma highlights to Pharma Uptoday members, Monthly magazine Volume 5 has been released with
News Uptoday
New Guidance
Audit Findings
483 Observations
- 483 of Downing Labs
- 483 of Impax Laboratories
FDA Recall letter observations
- Unique Pharmaceuticals Ltd
Warning Letters
- Pharmacy Creations, NJ
- Trifarma S.p.A., Italy
- Zhejiang Jiuzhou Pharmaceutical Co., China
EMA Non-Compliance Reports
- WOCKHARDT LIMITED, India
- SIMS Società Italiana Medicinali Scandicci srl, Italy
- SCM PHARMA LIMITED, UK
Regulations of the Month
§ 211.167 Special testing requirements
§ 211.170 Reserve Samples
§ 211.176 Penicillin contamination
IN THIS SUMMARY
The United States Food and Drug Administration (FDA) has significant reach in the American economy, ranging from medicines and medical devices to items on the grocery store shelves. Since its inception in 1906, the agency has faced a variety of technical and political challenges. Looking ahead, the FDA faces many new demands that could enlarge the agency’s already expansive mandate. New responsibilities may include the cost of medicine, consumers’ pursuit of perfection through drugs, consumer lifestyles, tobacco, and counterterrorism. As the nature of public health changes over time, it is inevitable that the FDA’s scope and responsibilities will change as well. In Inside the FDA, Fran Hawthorne explains the history of the FDA, how its processes work, and what the future may hold for this government agency.
SUBSCRIBE TODAY
http://www.bizsum.com/summaries/inside-fda
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014Sathish Vemula
To recap the previous month's pharma highlights to Pharma Uptoday members, Monthly magazine Volume 5 has been released with
News Uptoday
New Guidance
Audit Findings
483 Observations
- 483 of Downing Labs
- 483 of Impax Laboratories
FDA Recall letter observations
- Unique Pharmaceuticals Ltd
Warning Letters
- Pharmacy Creations, NJ
- Trifarma S.p.A., Italy
- Zhejiang Jiuzhou Pharmaceutical Co., China
EMA Non-Compliance Reports
- WOCKHARDT LIMITED, India
- SIMS Società Italiana Medicinali Scandicci srl, Italy
- SCM PHARMA LIMITED, UK
Regulations of the Month
§ 211.167 Special testing requirements
§ 211.170 Reserve Samples
§ 211.176 Penicillin contamination
IN THIS SUMMARY
The United States Food and Drug Administration (FDA) has significant reach in the American economy, ranging from medicines and medical devices to items on the grocery store shelves. Since its inception in 1906, the agency has faced a variety of technical and political challenges. Looking ahead, the FDA faces many new demands that could enlarge the agency’s already expansive mandate. New responsibilities may include the cost of medicine, consumers’ pursuit of perfection through drugs, consumer lifestyles, tobacco, and counterterrorism. As the nature of public health changes over time, it is inevitable that the FDA’s scope and responsibilities will change as well. In Inside the FDA, Fran Hawthorne explains the history of the FDA, how its processes work, and what the future may hold for this government agency.
SUBSCRIBE TODAY
http://www.bizsum.com/summaries/inside-fda
Pharmaceutical Marketing: An Analysis of the Pharmaceutical Industry in Bangl...Masrur Rahman Faraz
The report includes interviews from three prominent pharmaceutical professionals in the Bangladeshi Pharmaceutical Industry. The market was approx. $1.5B in 2016, with a 10% growth. It meets 97% of the local demand & exports to 62+ countries in Asia, Africa & Europe. The long-term investment focus should be on chronic care market, although the acute care segment is preferred for short-term gains. WTO has exempted Bangladesh from TRIPS until 2031, which is a major opportunity for the country.
This project comprises market overview of one of the leading pharmaceutical manufacturing company Pfizer. It consists company's historical background, Market status, Major critics faced by them. which is helpful for MBA & Marketing students and for further share holders looking up for companies outline. Prepared and submitted on October 2021
Evaluate the role of leadership on organizational behaviorProv.docxhumphrieskalyn
Evaluate the role of leadership on organizational behavior
Provide the name of the corporation you will be using as the basis for this project.
Provide the organization’s purpose or mission statement.
Describe the organization's industry.
Provide the name and position of the person interviewed during this portion of the assignment (indicate as much pertinent information (e.g., length of service with company, previous roles in the company, educational background, etc.).
Provide the list of interview questions you asked the manager/executive.
Indicate which two - three of the following concepts from this competency that you intend to evaluate the organization/team on and describe the company’s/team’s current situation with each topic you’ve selected:
Power and politics
Communication
Organizational leadership
Organizational structure
Organizational change
Provide citations in APA format for any references.
.
Evaluate the role that PKI plays in cryptography.Ensure that you.docxhumphrieskalyn
Evaluate the role that PKI plays in cryptography.
Ensure that your initial discussion posting has been created by Thursday of each week and then you respond to a minimum of two other learners during the week. Your response must build upon the initial learner's comments. Please ensure that you properly APA format your writing. 500 words.
You must also use a scholarly source
.
More Related Content
Similar to Eugene D. Fanning Center for Business Communication 01-01Men.docx
Pharmaceutical Marketing: An Analysis of the Pharmaceutical Industry in Bangl...Masrur Rahman Faraz
The report includes interviews from three prominent pharmaceutical professionals in the Bangladeshi Pharmaceutical Industry. The market was approx. $1.5B in 2016, with a 10% growth. It meets 97% of the local demand & exports to 62+ countries in Asia, Africa & Europe. The long-term investment focus should be on chronic care market, although the acute care segment is preferred for short-term gains. WTO has exempted Bangladesh from TRIPS until 2031, which is a major opportunity for the country.
This project comprises market overview of one of the leading pharmaceutical manufacturing company Pfizer. It consists company's historical background, Market status, Major critics faced by them. which is helpful for MBA & Marketing students and for further share holders looking up for companies outline. Prepared and submitted on October 2021
Evaluate the role of leadership on organizational behaviorProv.docxhumphrieskalyn
Evaluate the role of leadership on organizational behavior
Provide the name of the corporation you will be using as the basis for this project.
Provide the organization’s purpose or mission statement.
Describe the organization's industry.
Provide the name and position of the person interviewed during this portion of the assignment (indicate as much pertinent information (e.g., length of service with company, previous roles in the company, educational background, etc.).
Provide the list of interview questions you asked the manager/executive.
Indicate which two - three of the following concepts from this competency that you intend to evaluate the organization/team on and describe the company’s/team’s current situation with each topic you’ve selected:
Power and politics
Communication
Organizational leadership
Organizational structure
Organizational change
Provide citations in APA format for any references.
.
Evaluate the role that PKI plays in cryptography.Ensure that you.docxhumphrieskalyn
Evaluate the role that PKI plays in cryptography.
Ensure that your initial discussion posting has been created by Thursday of each week and then you respond to a minimum of two other learners during the week. Your response must build upon the initial learner's comments. Please ensure that you properly APA format your writing. 500 words.
You must also use a scholarly source
.
Evaluate the presence and effects of alteration in the homeostatic s.docxhumphrieskalyn
Evaluate the presence and effects of alteration in the homeostatic state secondary to gender, genetic, ethnic and temporal variables
Select one of the case studies below, and include in your discussion an evaluation of the presence and effects of alteration in the homeostatic state secondary to gender, genetic, ethnic, and temporal variables.
Requirements:
Make sure all of the topics in the case study have been addressed.
Cite at least three sources; journal articles, textbooks or evidenced-based websites to support the content.
All sources must be within 5 years.
Do not use .com, Wikipedia, or up-to-date, etc., for your sources.
Case Study 1
Structure and Function of the Respiratory System
Brad is 45 years old and has been working as a coal cutter in a mine for the last 25 years. He likes the job because it pays well and the same mine had employed his father. Like many of his colleagues, Brad has had problems with a chronic cough. He has avoided his annual checkups for fear that he will be told he has “black lung,” or coal worker’s pneumoconiosis. The disease causes fibrosis, decreased diffusing capacity, and permanent small airway dilation. In later stages, pulmonary capillaries, alveoli, and airways are destroyed.
How can the disease described above create a mismatch between ventilation and perfusion? Use your understanding of alveolar dead space and physiologic shunt to explain your answer.
Individuals with chronic obstructive pulmonary disease have more difficulty exhaling than inhaling. Why is this so?
In general terms, what mechanisms in lung disease can affect diffusing capacity across alveolar membranes? Use the Fick law to explain your answer.
Case Study 2
Respiratory Tract Infections, Neoplasms, and Childhood Disorders
Patricia was called at work by a woman at the local daycare center. She told Patricia to come and pick up her son because he was not feeling well. Her son, three-and-a-half-year-old Marshall, had been feeling tired and achy when he woke up. While at daycare, his cheeks had become red and he was warm to touch. He did not want to play with his friends, and by the time Patricia arrived, he was crying. Later that afternoon, Marshall’s condition worsened. He had fever, chills, a sore throat, runny nose, and a dry hacking cough. Suspecting Marshall had influenza, Patricia wrapped him up and took him to the community health care clinic.
Why did Marshall’s presentation lead Patricia to think he had influenza and not a cold? Why is it important to medically evaluate and diagnose a potential influenza infection?
Describe the pathophysiology of the influenza virus. Outline the properties of influenza A antigens that allow them to exert their effects in the host.
Marshall may be at risk at contracting secondary bacterial pneumonia. Why is this so? Explain why cyanosis may be a feature associated with pneumonia.
Case Study 3
Disorders of Ventilation and Gas Exchange
Emmanuel and his mother live in an.
Evaluate the role of a digital certificate in cryptography. How doe.docxhumphrieskalyn
Evaluate the role of a digital certificate in cryptography. How does it impact the security posture of an organization?
Write a minimum of 2 to pages
The Paper must include scholarly references of 2
Make sure to follow APA Guidelines
.
Evaluate the merits of Piaget’s stage theory for explaining cognitiv.docxhumphrieskalyn
Evaluate the merits of Piaget’s stage theory for explaining cognitive development.
Discuss evidence that supports his theory as well as evidence that calls it into question.
Discuss your personal opinions about stage theories in general. Who are some of the major detractors and how would you address them?
.
Evaluate the notion that white collar offenders are intrinsically di.docxhumphrieskalyn
Evaluate the notion that white collar offenders are intrinsically different from non-offenders. What are the principal elements of the demonic, biogenetic, psychological and sociogenic perspectives on this question, and the evidence for an answer to the question within these perspectives? Which individualistic attributes of white collar offenders do you regard as meriting further systematic study, and why?
.
EV 551 Hazardous Materials Assessment – Summer2020Homework 1 – 4.docxhumphrieskalyn
EV 551 Hazardous Materials Assessment – Summer2020
Homework 1 – 40 points
1. Which of the following is not a part of the HAZWOPER process:
a.
Recognition of hazards
b.
Evaluation of hazards
c.
Control of hazards
d.
Information gathering
e.
Safety from hazards
f.
All are part of the process
2.
Hazardous waste site workers must:
a.
Receive 40-hour OSHA 1910.120 training plus 24 hours of field supervision if exposed over the PEL
b.
Receive 40-hour training plus 8 hours field supervision if exposed below the PEL and when respirators are not required
c.
8-hour annual refresher training
d.
All of the above
3.
First Responder Operations level training allows persons to:
a.
Witness or discover a release
b.
Perform defensive actions
c.
Stop the release
d.
A and B are true
e.
All of the above
4.
Recognition of hazards includes:
a.
Identifying the materials involved in the release
b.
Identifying the degree of hazards present
c.
Provide the level of protection needed for site workers
d.
A and B are correct
e.
All of the above
5.
The most important response activity at a hazardous waste work site is:
a.
Evaluation of hazards
b.
Control of hazards
c.
Recognition of hazards
d.
Safety precautions
6.
Frequent hazard types found at response sites include:
a.
Physical hazards
b.
Biological hazards
c.
Chemical hazards
d.
Mechanical hazards
e.
All of the above
7.
The purpose of initial control activities is to:
a.
Immediately assess clean up alternatives
b.
Provide time to responders to address long-term hazards
c.
Slowly size up response activities
d.
Both A and B are correct
e.
None of the above
8.
Spill reporting is covered by which of these federal regulations:
a.
Superfund
b.
DOT
c.
RCRA
d.
Clean Water Act
e.
A, B, and D are correct
9.
The effects of toxic materials on the human body are determined by:
a.
Routes of exposure
b.
Dose
c.
Duration and frequency of exposure
d.
All of the above
10.
What are the four major pathways that chemical substances can enter the body?
a.
___________________________________________________
b.
___________________________________________________
c.
___________________________________________________
d.
___________________________________________________
11.
What is the primary route of exposure to hazardous waste site workers or incident
responders?
a.
Ingestion
b.
Dermal absorption
c.
Inhalation
d.
Both a and b are correct
12.
Dermal absorption may occur with which form(s) of a chemical:
a.
Solid
b.
Liquid
c.
Aerosol
d.
Mist
e.
All of the above
13.
The dose-response curve illustrates:
a.
The indirect relationship between dose and response
b.
The direct relationship between dose and response
c.
The average number of affected individuals
d.
None of the above
14.
For most chemicals, a low dose does that does not show an appreciable hazard to exposed individuals is called the:
a.
LOAEL
.
Evaluate the history of cryptography from its origins. Analyze how .docxhumphrieskalyn
Evaluate the history of cryptography from its origins. Analyze how cryptography was used and describe how it grew within history.
The writing assignment requires a minimum of two written pages to evaluate the history. You must use a minimum of three scholarly articles to complete the assignment. The assignment must be properly APA formatted with a separate title and reference page.
.
Evaluate the evidence provided by Apollo Shoes.Decide how to s.docxhumphrieskalyn
Evaluate
the evidence provided by Apollo Shoes.
Decide
how to structure the audit report for the provided evidence.
Compose
an audit report
reflecting the appropriate length, sections, and content for the provided information.
Include
a description of the evidence, the accounting sampling and testing procedures used, and a brief description of the value of the audit report
Can anyone do this assignement. It is due by 9pm 11/12/2012 Eastern Standard Time..
.
Evaluate the Health History and Medical Information for Mrs. J.,.docxhumphrieskalyn
Evaluate the Health History and Medical Information for Mrs. J., presented below.
Based on this information, formulate a conclusion based on your evaluation, and complete the Critical Thinking Essay assignment, as instructed below.
Health History and Medical Information
Health History
Mrs. J. is a 63-year-old married woman who has a history of hypertension, chronic heart failure, and chronic obstructive pulmonary disease (COPD). Despite requiring 2L of oxygen/nasal cannula at home during activity, she continues to smoke two packs of cigarettes a day and has done so for 40 years. Three days ago, she had sudden onset of flu-like symptoms including fever, productive cough, nausea, and malaise. Over the past 3 days, she has been unable to perform ADLs and has required assistance in walking short distances. She has not taken her antihypertensive medications or medications to control her heart failure for 3 days. Today, she has been admitted to the hospital ICU with acute decompensated heart failure and acute exacerbation of COPD.
Subjective Data
Is very anxious and asks whether she is going to die.
Denies pain but says she feels like she cannot get enough air.
Says her heart feels like it is "running away."
Reports that she is exhausted and cannot eat or drink by herself.
Objective Data
Height 175 cm; Weight 95.5kg.
Vital signs: T 37.6C, HR 118 and irregular, RR 34, BP 90/58.
Cardiovascular: Distant S1, S2, S3 present; PMI at sixth ICS and faint: all peripheral pulses are 1+; bilateral jugular vein distention; initial cardiac monitoring indicates a ventricular rate of 132 and atrial fibrillation.
Respiratory: Pulmonary crackles; decreased breath sounds right lower lobe; coughing frothy blood-tinged sputum; SpO2 82%.
Gastrointestinal: BS present: hepatomegaly 4cm below costal margin.
Intervention
The following medications administered through drug therapy control her symptoms:
IV furosemide (Lasix)
Enalapril (Vasotec)
Metoprolol (Lopressor)
IV morphine sulphate (Morphine)
Inhaled short-acting bronchodilator (ProAir HFA)
Inhaled corticosteroid (Flovent HFA)
Oxygen delivered at 2L/ NC
Critical Thinking Essay
In 750-1,000 words, critically evaluate Mrs. J.'s situation. Include the following:
Describe the clinical manifestations present in Mrs. J.
Discuss whether the nursing interventions at the time of her admissions were appropriate for Mrs. J. and explain the rationale for each of the medications listed.
Describe four cardiovascular conditions that may lead to heart failure and what can be done in the form of medical/nursing interventions to prevent the development of heart failure in each condition.
Taking into consideration the fact that most mature adults take at least six prescription medications, discuss four nursing interventions that can help prevent problems caused by multiple drug interactions in older patients. Provide a rationale for each of the interventions you recommend.
Provide a health promotion .
Evaluate the current state of the health care system in Sacramento. .docxhumphrieskalyn
Evaluate the current state of the health care system in Sacramento. Read local newspaper articles, watch videos, and explore government and health care sites for information about challenges to the city’s health care needs (shortages, financial difficulties, privacy issues, etc.).
Propose a new or improved health care service that you would introduce into the community. Explain why the service is needed and how it would improve the community.
Design a new health care facility that would offer a new or an improved service to the community. Present a floor plan of the facility that includes the surface area, purpose for, and description of each space.
Write a 700 - to 1,050–word report about the state of health care in your selected city, your proposal for a new or improved service, and the floor plan of a facility to implement that service.
.
Evaluate the advantages and disadvantages of the various decis.docxhumphrieskalyn
Evaluate the advantages and disadvantages of the various decision-making tools listed (e.g., regular payback, discounted payback, net present value (NPV), internal rate of return (IRR), and modified internal rate of return).
Describe a project scenario in which you would recommend one method, or a combination of methods, as being more effective than others. Draw from your professional experience and/or additional research, and provide a rationale for your recommendation.
.
Evaluate some technologies that can help with continuous monitoring..docxhumphrieskalyn
Evaluate some technologies that can help with continuous monitoring. One example of many is Cyberscope, an automated reporting tool for security reporting that receives recurring data feeds to assess the security posture of IT systems. Discuss the pros and cons of using continuous monitoring tools and make other suggestions to improve continuous monitoring.
In the second week, discuss the major challenges in continuous monitoring of information systems security.
*will send 2 classmates after completion of discussion so you can respond!
.
Evaluate progress on certification plansReport your prog.docxhumphrieskalyn
Evaluate progress on certification plans
Report your progress on the Certification Plan completed in Week 1 and submitted in Week 4.
What have you done to prepare for your certification?
Have you completed the scheduled tasks assigned on your timeline? If not, what are your plans to stay on schedule?
Rubric:
Quality of Work Submitted:
The extent of which work meets the assigned criteria and work reflects graduate level critical and analytic thinking.--
Quality of Work Submitted:
The purpose of the paper is clear.--
Written Expression and Formatting
Paragraph and Sentence Structure: Paragraphs make clear points that support well developed ideas, flow logically, and demonstrate continuity of ideas. Sentences are clearly structured and carefully focused--neither long and rambling nor short and lacking substance.--
.
Evaluate how you have achieved course competencies and your plans to.docxhumphrieskalyn
Evaluate how you have achieved course competencies and your plans to develop further in these areas. The course competencies for this course are as follows:
Explore the historical evolution of the advance practice nurse.
Differentiate the roles and scope of practice for nurses working in advanced clinical, education, administration, informatics, research, and health policy arenas.
Analyze attributes of the practice arena such as access and availability, degree of consumer choice, competition, and financing that impact advanced practice nurses and their ability to effectively collaborate with other health professionals.
Integrate evidence from research and theory into discussions of practice competencies, health promotion and disease prevention strategies, quality improvement, and safety standards.
Identify collaborative, organizational, communication, and leadership skills in working with other professionals in healthcare facilities and/or academic institutions.
Synthesize knowledge from values theory, ethics, and legal/regulatory statutes in the development of a personal philosophy for a career as an advanced practice nurse.
.
Evaluate how information privacy and security relates to the Interne.docxhumphrieskalyn
Evaluate how information privacy and security relates to the Internet, which is the major information conduit for businesses and individuals.
Write a paragraph of at least 200 words addressing the following: Explain how your expectations for Internet privacy differ for the following situations: Accessing the web at home, at work, and in a public setting, such as a library computer lab or Wi–Fi zone. What is the basis for your expectations? Is it legal to use your neighbors’ wireless Internet signal? Is it ethical? Explain your reasoning.
.
Evaluate assessment of suicide in forensic settings andor cri.docxhumphrieskalyn
Evaluate assessment of suicide in forensic settings and/or criminal justice institutions by addressing the following:
Who would serve on the task force?
Who would be involved in suicide prevention or identification if you were able to intervene at the institution?
What would the interventions look like? What would be some of the policies and procedures that you might implement to ensure that best practices are met?
Provide specific examples based on your current or future forensic role.
Include an analysis of your own prejudices and biases regarding inmate suicides (e.g., consider a child murderer).
.
Evaluate different approaches to ethical decision making. Then, choo.docxhumphrieskalyn
Evaluate different approaches to ethical decision making. Then, choose one of them to apply to an ethical issue you have identified.
By successfully completing this assessment, you will demonstrate your proficiency in the following course competencies and assessment criteria:
Competency 1: Evaluate the parameters for ethical decision making in 21st century multicultural business environments.
Evaluate the parameters of various ethical decision-making approaches.
Competency 3: Evaluate organizational policy within the framework of ethical standards.
Analyze an ethical dilemma using an ethical decision-making approach.
Assess the validity of a resolution suggested by a selected ethical decision-making approach.
Competency 4: Communicate effectively.
Communicate the analysis of ethical decision making clearly and effectively.
.
Evaluate and grade websites in terms of their compliance with PL pri.docxhumphrieskalyn
Evaluate and grade websites in terms of their compliance with PL principles. You will first do this with a local government site (Project 1a) and then with a federal site (Project 1b). You will perform the same analysis and evaluation that is done by those who volunteer with the Center for Plain Language to review and grade federal websites as part of the plain language Federal Report Card.
.
Evaluate at least (2) factors that make financial statement analys.docxhumphrieskalyn
Evaluate at least (2) factors that make financial statement analysis essential to management, investors, and creditors. Provide a rationale for your response.
Imagine you are considering investing in a corporation. Examine the key information you would look for in a company’s financial statements and explain why this information would be important to you. Suggest at least two (2) financial statement analysis tools you would use to evaluate this company’s financial statements. Provide a rationale for your suggestions.
.
Safalta Digital marketing institute in Noida, provide complete applications that encompass a huge range of virtual advertising and marketing additives, which includes search engine optimization, virtual communication advertising, pay-per-click on marketing, content material advertising, internet analytics, and greater. These university courses are designed for students who possess a comprehensive understanding of virtual marketing strategies and attributes.Safalta Digital Marketing Institute in Noida is a first choice for young individuals or students who are looking to start their careers in the field of digital advertising. The institute gives specialized courses designed and certification.
for beginners, providing thorough training in areas such as SEO, digital communication marketing, and PPC training in Noida. After finishing the program, students receive the certifications recognised by top different universitie, setting a strong foundation for a successful career in digital marketing.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
Model Attribute Check Company Auto PropertyCeline George
In Odoo, the multi-company feature allows you to manage multiple companies within a single Odoo database instance. Each company can have its own configurations while still sharing common resources such as products, customers, and suppliers.
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
Francesca Gottschalk - How can education support child empowerment.pptxEduSkills OECD
Francesca Gottschalk from the OECD’s Centre for Educational Research and Innovation presents at the Ask an Expert Webinar: How can education support child empowerment?
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Eugene D. Fanning Center for Business Communication 01-01Men.docx
1. Eugene D. Fanning Center for Business Communication 01-01
Mendoza College of Business
University of Notre Dame
Bayer Corporation:
The Recall of Phenylpropanolamine (PPA)
For years, the consumer care division of Bayer Corporation has
successfully marketed a
number of well-known brands that have earned the trust of
American consumers. These brands
include Bayer aspirin, Aleve analgesic, Phillips’ Milk of
Magnesia, One-A-Day vitamins, and
Alka-Seltzer medicines. Responding to concerns raised about
an ingredient found in some of its
products, Bayer and several other drug manufacturers co-
sponsored a study to assess the safety of
this ingredient. Not only was Bayer interested in the results,
the Food and Drug Administration
(FDA) was interested as well.
The results of the study concluded that the ingredient carried a
risk. However, Bayer and
the FDA did not agree on the severity of the risk. As a result,
Bayer’s supply chain was not
prepared when the FDA requested a voluntary recall of all
products containing the ingredient.
Perhaps more importantly, Bayer management had not
anticipated the media’s interpretation of
the FDA actions. The resulting headlines would likely tarnish
the reputation of one of Bayer’s
key brands, Alka-Seltzer. If not addressed properly by the
3. used in a spreadsheet, or transmitted in any form by any
means – electronic, mechanical, photocopying, recording, or
otherwise – without permission.
2
1 http://www .bayer us.co m/ab out/o rg.htm
2
Co mpe titive M edia R epo rting. Ad $ Sum mary: January-
December 1998 , Book I . New York: 1999, p. 98.
In 1899, Bayer invented aspirin and changed the world forever.
Western medicine finally had an
inexpensive and reliable means for relieving pain and reducing
fevers. Today, Bayer aspirin is a
staple in most medicine chests and has been found to prevent
blood clots, thereby reducing the
risk of strokes and heart attacks.
Bayer Corporation invests 80 percent of its research and
development dollars in health
care and life sciences projects. It operates 50 sales offices and
50 manufacturing operations,
while marketing some 10,000 products from nine divisions:
agriculture; coatings and colorants;
consumer care; diagnostics; fibers, additives, and rubber;
industrial chemicals; pharmaceuticals;
plastics; and polyurethanes. (Exhibit 2)1 While Bayer’s
flagship product, aspirin, has been a
strong sales performer throughout its existence, the company’s
robust research and development
budget has enabled it to bring several other breakthrough over-
the-counter (OTC) pharmaceutical
4. products to the market.
Alka-Seltzer Medicines
Alka-Seltzer is an example of a breakthrough product
introduced by Bayer. The original
product was developed in the late 1920s when it was discovered
that the main ingredients,
acetylsalicylic acid and sodium bicarbonate, helped to combat
flu symptoms. Today, products
marketed under the brand are available in over 50 countries
worldwide. The brand was first
marketed in 1931 and gained mass popularity in the 1950s
through advertisements about its
effervescent nature, often featuring the product’s mascot,
“Speedy.” However, Alka-Seltzer
remedies are also currently available in liqui-gel and non-
effervescent tablet forms. Though it
was originally marketed to provide relief of headaches, stomach
problems, and heartburn, many
of today’s Alka-Seltzer products are specifically formulated to
provide relief of cold and flu
symptoms. These products are known as Alka-Seltzer Plus cold
medicines. Bayer had invested
considerable resources in cultivating the Alka-Seltzer Plus
brand. By 1998, annual advertising
expenditures totaled over $44.8 million, of which 62% was
spent on promoting the effervescent
tablets.2
A Key Ingredient: PPA
Perhaps the most common symptom of cold and flu is sinus
congestion. Many remedies
contain phenylpropanolamine (PPA) because the chemical is
highly effective in providing relief
5. of sinus congestion. PPA is a stimulant similar to amphetamine
and is also used in the
3
3 http://healthwatch.medscape.com
4 “Phe nylpro pan olam ine & Risk o f Hem orrha gic Stro ke –
F inal Re por t of HS P.” Y ale U niversity,
May 2000.
5 http://www.fda.gov
manufacture of weight loss drugs because of its ability to act as
an appetite suppressant. In
addition to Alka-Seltzer Plus, PPA can be found in other
popular cold medicine brands such as
Comtrex, Dimetapp, and Robitussin.3 The medication has been
on the market for 50 years with
annual usage surpassing one billion doses.4 While Alka-Seltzer
Plus cold medicines are
available in both effervescent and liqui-gel forms, only the
effervescent medicines contain PPA.
Federal Drug Administration Organizational Overview
As a unit of the U.S. Department of Health and Human Services,
the FDA plays a critical
role in the safety and security of the public health. Its mission
statement is as follows:5
1. To promote the public health by promptly and efficiently
reviewing clinical research and
taking appropriate action on the marketing of regulated products
6. in a timely manner;
2. With respect to such products, protect the public health by
ensuring that foods are safe,
wholesome, sanitary, and properly labeled; human and
veterinary drugs are safe and
effective; there is reasonable assurance of the safety and
effectiveness of devices intended
for human use; cosmetics are safe and properly labeled, and;
public health and safety are
protected from electronic product radiation;
3. Participate through appropriate processes with
representatives of other countries to reduce
the burden of regulation, harmonize regulatory requirements,
and achieve appropriate
reciprocal arrangements; and,
4. As determined to be appropriate by the Secretary (of Health
and Human Services), carry
out paragraphs (1) through (3) in consultation with experts in
science, medicine, and
public health, and in cooperation with consumers, users,
manufacturers, importers,
packers, distributors, and retailers of regulated products.
Of the several regulatory bodies within the FDA, the Center for
Drug Evaluation and
Research (CDER) focuses on both prescription and OTC drug
markets. More specifically, all
OTC initiatives are handled within CDER at the Office of Drug
Evaluation V, Division of OTC
Products. (Exhibit 3)
7. 4
6
U.S. Code of Federal Regulations, 21 CFR 7.40
7
21 CFR 7.3m
FDA Drug Recall Policy and Process
As defined by the FDA, a recall is a “voluntary action that takes
place because
manufacturers and distributors carry out their responsibility to
protect the public health and well-
being from products that present a risk of injury or gross
deception or are otherwise defective.”6
In the event that manufacturers or distributors refuse or fail to
undertake a FDA requested recall,
the FDA may pursue a court approved seizure. An ad hoc
committee of FDA scientists evaluates
all drugs being recalled or considered for recall. This
committee may also elect to seek outside
consultation and expertise as appropriate.
There are several main factors analyzed by the committee.
First, it must determine
whether the drug has already caused any disease or injury.
Next, the committee considers
whether or not future exposure to the drug could cause health
hazards such as illness or death.
Finally, they assess the likelihood of the hazards occurring and
the resulting consequences, short
and long-term. Based upon these general guidelines, the FDA
8. will decide whether or not a drug
should be recalled.
If a recall is deemed necessary, the FDA assigns a classification
to the recalled drug. The
classifications are defined as follows:7
· Class I – reasonable probability that exposure to or use of the
drug will cause serious
adverse health consequences or death.
· Class II – remote probability that exposure to or use of the
drug may cause temporary or
medically reversible adverse health conditions.
· Class III – use of or exposure to the drug is not likely to cause
adverse health
consequences.
In the event of a recall, the FDA will immediately notify all
affected companies by phone
or by visitation from an authorized FDA representative,
followed by a written confirmation by
mail or telegram to a company official. The notification
specifies the violation, the hazard
classification, proposed recall strategy, and other instructions.
Upon receiving the notification,
the company may be asked to provide the FDA with additional
information pertinent to the drug
being recalled.
Following notification, a drug manufacturer develops a recall
strategy in accordance with
FDA guidelines. These guidelines govern the depth of the
9. recall, public communication, and
effectiveness checks. Depending upon how hazardous the drug
is and the extent of its
5
8 21 CFR 7.45
9 21 CFR 7.49c
10
21 CFR 7.45b3
distribution, the recall depth can span from wholesale levels to
retail/consumer levels. Each
physical product recall is unique to the circumstances
surrounding the situation. Ultimately, the
FDA will specify to what level the recall should extend.
The FDA may also issue warnings to alert the public of the
recall. This is reserved for
“urgent situations where other means for preventing use of the
recalled product appear
inadequate.”8 Ordinarily, the FDA will issue public warnings
through several channels including
the general news media (national, regional, or local) or
specialized news media such as the trade
press to reach specific target segments (i.e., physicians, medical
organizations, etc.). For a firm
that decides to issue its own public warnings, the format,
content, and extent of the
communications must be submitted to the FDA for review and
approval. All public
communications must:9
10. · Display the product by name, size, lot number(s), code(s),
serial number(s) and
any other descriptive labeling to accurately identify the product.
· Explain the reason for the recall and the associated hazard.
· Provide instructions for product returns.
· Identify a means for recipients to communicate and contact the
company.
The third and final component of a recall strategy is the
effectiveness check. The purpose
of an effectiveness check is to verify that affected parties have
received the recall notifications
and taken action. Normally, the drug manufacturer will be
responsible for verifying the
effectiveness of the recall notification, but the FDA can assist
and perform audits when
necessary. The FDA categorizes effectiveness checks into five
levels:10
1. Level A – 100% effectiveness
2. Level B – Some of the recipients contacted, but not all
3. Level C – Less than 10% contacted
4. Level D – Less than 2% contacted
5. Level E – No effectiveness
6
11. 11 21 CFR 7.55a
12
Jick, Aselton, Hunter. “PPA and Cerebral Hemorrhage,”
Lancet, 1984.
13
“Phenylpropanolamine & Risk of Hemorrhagic Stroke – Final
Report of the HSP.” Yale University, May
2000.
14
http://www .fda.go v/cde r/drug /infopa ge/pp a/adv isory.htm
The FDA will terminate a recall when it determines that “all
reasonable efforts have been
made to remove or correct the product in accordance with the
recall strategy, and when it is
reasonable to assume that the product subject to the recall has
been removed and proper
disposition or correction has been made commensurate with the
degree of hazard of the recalled
product.”11
The PPA Controversy
PPA has been on the market for over fifty years, and the FDA
had classified the chemical
as “safe and effective.” However, in the late 1970s, some
concerns over its possible health
hazards began to emerge. Several doctors theorized that PPA
caused blood pressure to rise
above normal levels, thus leading to stroke. In 1984, a research
study concluded that any
12. hemorrhagic risk related to PPA, if present at all, was very
small (less than 1% likelihood).12 By
the late 1980s, lawsuits against drug manufacturers of
medicines containing PPA were growing,
especially the legal claims from patients and consumers of PPA
alleging misconduct against the
drug companies. Furthermore, case reports from medical
organizations describing the
occurrence of strokes after PPA ingestion were climbing.
In response to growing concerns, the FDA and several drug
manufacturers jointly
commissioned a research study called the Hemorrhagic Stroke
Project (HSP) with the Yale
University School of Medicine in late 1994. The study was
comprised of 702 case subjects and
1,376 control subjects. The main purpose was to identify if
there was an association between
hemorrhagic stroke and the PPA found in cold remedies and
appetite suppressants. By the end of
the research study in May 2000, Yale University determined
that “PPA increases the risk for
hemorrhagic stroke. For both individuals considering use of
PPA and for policy makers, the HSP
provides important data for a contemporary assessment of risks
associated with use of PPA.”13
On October 19, 2000, the FDA’s Nonprescription Drugs
Advisory Committee (NDAC)
discussed this report and other information on PPA. The NDAC
determined that there is an
association between PPA and hemorrhagic stroke. They
recommended that PPA “not be
considered generally recognized as safe for over-the-counter use
as a nasal decongestant or for
weight control.”14
13. 7
15 Ibid.
16
FDA Letter to Manufacturers of Drug Products Containing
Phenylpropanolamine, November 3, 2000.
17
http://www .alka-seltz er.co m/info_ ppa .htm
18
Ibid.
Media Interpretation of the FDA’s Actions
On November 3, 2000, Janet Woodcock, M.D., Director at the
Center for Drug
Evaluation and Research issued a written statement addressed to
the senior management at Bayer
Corporation, as well as to other OTC manufacturers (Exhibit 4).
In the letter, Woodstock
referred to the report that the FDA received from the
researchers at the Yale University School of
Medicine. The Yale report’s research data suggested that PPA
increases the risk for hemorrhagic
stroke (bleeding into the brain or into tissue surrounding the
brain) in women.15 The report also
determined that men who used PPA could be at risk.
Woodcock’s statement continued that, “as
an interim measure to protect the public health, you (OTC
manufacturers) should voluntarily
discontinue marketing any drug products containing
14. phenylpropanolamine. If applicable, you
may reformulate such products to remove the
phenylpropanolamine ingredient.”16
As the news media became aware of this notice by the FDA,
different interpretations of
the warning began to surface in the headlines. The headline
from the November 7, 2000 Wall
Street Journal read “FDA Bans Use of Chemical Tied to
Strokes.” Similarly, the USA Today
headline from the same day reported, “Drugmakers, stores move
on FDA ban – Reformulated
remedies on way for colds.” The New Jersey Star-Ledger and
Pittsburgh Post-Gazette also
reported that the FDA would take steps to ban all use of PPA in
cold remedies and appetite
suppressants.
In reality, the FDA never issued a ban on the sale or use of
PPA, but rather requested a
voluntary recall of the product by the manufacturer’s whose
products contained the chemical.
Given the portrayals of the major newspapers, the public
reaction had the potential to be much
stronger than what was intended by the FDA or anticipated by
companies like Bayer. Now,
Bayer had to address the public perception that the FDA had
banned the use of PPA, making cold
remedies, such as Alka-Seltzer, dangerously unsafe.
Bayer’s Dilemma
It is clearly ironic that Bayer was among several cold medicine
manufacturers who
funded the Yale University study that served as the basis for the
FDA’s decision. Despite the
15. conclusions of the FDA, Bayer management still believed in the
safety of all Bayer products,
including those containing PPA.17 However, management was
also intent on maintaining the
trust and confidence of Bayer consumers.18 These facts would
undoubtedly influence the
8
19 “Phenylpropanolamine & Risk of Hemorrhagic Stroke - Final
Report of the HSP,” Yale University, May
200 0.
decision of whether or not to comply with the FDA’s requested
voluntary recall of all medicines
containing PPA as an ingredient.
Several cost considerations would also impact Bayer’s decision.
At the time of the
FDA’s decision, management felt the costs of implementing the
recall had the potential to reach
$60 million.19 Bayer would have to reimburse all retailers
carrying its effervescent medicines for
the costs of physically removing and returning the products to
Bayer. Additionally, money spent
on advertising campaigns, point-of-sale promotional displays,
and slotting fees for the
effervescent medicines would be lost. Finally, Bayer would
have to make a decision about
outstanding promotions that had been sent to consumers prior to
the issuance of the FDA’s
decision. One such promotion was a coupon entitling customers
who purchased an Alka-Seltzer
Plus product to a free container of orange juice.
16. These outstanding consumer promotions were especially
problematic considering the
dynamics of supplying Alka-Seltzer Plus to retailers. Demand
forecasts are prepared well ahead
of anticipated deliveries because the production lead-time for
Alka-Seltzer Plus products, both
effervescent and liqui-gels, is approximately three months. The
FDA’s call for a voluntary
withdrawal of PPA products took place in early November 2000,
the beginning of what is
considered the peak season for cold and flu medicines. Bayer
had not anticipated the FDA’s
decision, and the production of liqui-gels was not adjusted
during the months preceding the peak
season. If a recall were implemented, the effervescent products
would become unavailable and
retailers would experience stock-outs of substitute Bayer
products. Supply of Bayer substitutes
would not be available to meet demand until after the
conclusion of the peak cold and flu season.
One thing was certain: if Bayer did not take action, the positive
brand equity of Alka-Seltzer
Plus, as well as the reputations of Bayer’s other OTC brands,
would suffer immensely.
9
Questions
1. How should Bayer respond to the media’s portrayal of the
voluntary recall as an FDA ban
of PPA?
17. 2. Should Bayer continue to claim that its products containing
PPA are safe? If so, should
this message be consistent with a voluntary recall of products
containing PPA?
3. What is the most effective medium for communicating
Bayer’s message? Is there a
danger of further misinterpretation by the media?
4. What marketing strategy should Bayer implement given the
outstanding Alka-Seltzer Plus
coupons and the company’s inability to supply the product or
comparable substitutes?
10
Exhibit 1: History of Alka-Seltzer
1931: Alka-Seltzer is introduced on the market.
1950s: Alka-Seltzer gains mass popularity through national
advertising.
1969: Alka-Seltzer Plus products are introduced on the market.
1970s: Health concerns about PPA begin to surface.
1980s: Lawsuits against OTC manufacturers are filed.
1984: The first study of the relationship between PPA and
strokes is conducted.
A minimal association is found.
1994: The FDA and OTC manufacturers jointly commission a
18. research study at
Yale University School of Medicine.
1995: Bayer introduces Alka-Seltzer Plus caplets.
1996: Bayer introduces Alka-Seltzer Plus liqui-gels.
May 2000: Yale University releases the results of the research
study to the FDA’s
Nonprescription Drugs Advisory Committee (NDAC).
October 2000: NDAC reviews the results and recommends that
PPA not be considered safe.
November 2000: The FDA requests a voluntary recall by the
OTC manufacturers of all products
containing PPA.
11
12
13
1
In the mid- I 970s, phenylpropanolamine was classified as
Category I (safe and effective) by two
OT C drug advisory review p anels. The Coug h-Cold P anel's
19. recomm endations o n phenylpro pano larnine as a
nasal decongestant appeared in the FEDER AL RE GIST ER of
Sep tember 9, 1976 (4 1 FR 38 312) and the
Miscellaneous Internal Panel's recommendations for weight
control use appeared on February 26, 1982 (47
FR 846 6). H owe ver, FD A de ferred its classificatio n of ph
enylpr opa nolam ine be cause of sub sequ ent safety
issues that were raised, pen ding com pletion of add itional
studies.
Exhibit 4: FDA Letter
DEPARTMENT OF HEALTH HUMAN SERVICES Food and
Drug Administration
Rockville MD 20857
November 3, 2000
De ar CE O o r Pre siden t:
This letter concerns drug products containing
phenylpropanolamine and its salts marketed by prescription or
over-
the-counter (OTC), which are now or have previously been
manufactured, relabeled, repacked, or distributed by your
firm. Phenylpropanolamine is currently available by
prescription and OTC as a nasal decongestant, and OTC for
weight control. Your firm is receiving this letter based on
20. information in the Food and Drug Administration's (FDA)
Drug Listing System or because you have a new drug
application (NDA) or abbreviated new drug application
(ANDA ) for a product containing phenylpropanolamine.
This letter is to inform you of recent developments relating to
phenylpropanolarnine. Earlier this year, FDA received
a report entitled "Phenylpropanolamine & Risk of Hemorrhagic
Stroke: Final Report of the Hemorrhagic Stroke
P r oj ec t" fr om sc ie nt is ts at Ya le U ni ve rs it y S ch o
ol of M e d ic in e. T hi s r ep o rt , w hi ch is on di sp la y i
n D o ck et No . 8 1 N -
0022 in the FDA Dockets M anagement Branch, states that the
data suggest that phenylpropanolamine increases the
risk for hemorrhagic stroke.
On O ctober 19; 2000 , the Agency's Nonprescription Drugs
Advisory Comm ittee (ND AC) discussed this report and
other information on phenylpropanolamine. NDAC determined
that there is.an association between
phenylpropanolamine and hemorrhagic stroke and recommended
that phenylpropanolamine not be considered
gene rally reco gnized as safe fo r OT C use as a na sal dec
onge stant or fo r weigh t contro l.1
Based on these recent developments, FDA intends to initiate
rulemaking to classify phenylpropanolamine as
21. nonmo nograp h (not genera lly recognized as safe a nd
effective) for O TC use. Based on the recen t research
findings,
FDA also has significant concern s about the co ntinued use of
p henylprop anolam ine in prescription d rug prod ucts.
FD A also intend s to take action to rem ove phen ylpro pan
olam ine from presc ription drug pro duc ts. FD A pla ns to
issue a P ublic H ealth A dviso ry on p henylp rop ano lamine
to alert c onsu mers and h ealth p rofessio nals ab out the repo
rt.
14
Page 2
FDA also believes that, as an interim measure to protect the
public health, you should voluntarily discontinue
mark eting an y drug pro duc ts conta ining ph enylpr opa nolar
nine. If ap plicab le, you m ay refo rmula te such p rod ucts to
remo ve the p henylp rop ano larnine ingred ient.
If you have any questions or want additional information,
including information about options for reformulating
products that contain pbenylpropanolarnine, please contact jerry
Racbanow or Robert Sherman at 301-827-2241.
Your cooperation and prompt attention to this matter will be
22. appreciated.
Since rely,
Jane t W ood coc k, M .D.
Director Center for Drug Evaluation and
Research
Page 1Page 2Page 3Page 4Page 5Page 6Page 7Page 8Page 9Page
10Page 11Page 12Page 13Page 14